The discovery of EGFR mutations and ALK rearrangements also contributed to the development of a new scale [37] of prognostic factors in patients with brain metastases of non-small cell lung carcinoma, taking into account the presence of EGFR mutations or ALK rearrangements. Here, EGFR is linked to non-small cell lung carcinoma.